Clinical trials: Invasive Breast Cancer
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Invasive
Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery
In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution…
- Trial name
- NCT06977698
- Testing
- OCT-Raman, AF-Raman
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
Invasive Breast Cancer
Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma
Retrospective observational study to evaluate c-MYC expression in non invasive and invasive mammry carcinoma
- Trial name
- NCT06357338
- Testing
- no intervention
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Marwa Mahmoud Hassan
Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
This is an open-label, single-arm, exploratory study planned to include 40 patients with HRD-positive HR +/HER2- advanced breast cancer treated with Adebrelimab in combination with fluzoparib.
- Conditions
- Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer, HRD Positive Advanced Breast Cancer
- Trial name
- NCT06254066
- Testing
- Adebrelimab plus Fluzoparib
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Invasive
Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.
We have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo.
- Trial name
- NCT00437879
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Sunnybrook Health Sciences Centre
Invasive Breast Carcinoma
Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
This randomized pilot trial studies how well exercise works in improving health and quality of life in breast cancer survivors. Participating in an exercise program to maintain physical activity may help to improve health and…
- Trial name
- NCT03679559
- Testing
- Best Practice, Exercise Intervention (home walking program and resistance training), Exercise Intervention (home-based Zumba program and resistance training)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Roswell Park Cancer Institute
Invasive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness
- Trial name
- DEAR (NCT01765049)
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Seoul National University Hospital
Invasive Breast Cancer
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- NCT03381092
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Peking University
Breast Cancer, Lobular Carcinoma
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
This study is being done in order to better understand the biology of an abnormal lesion found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in studying LCIS.
- Conditions
- Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer
- Trial name
- NCT00581750
- Testing
- Tissue specimen
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01409811
- Testing
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Ductal Carcinoma In Situ, Invasive Breast Cancer
The Prone Breast Radiation Therapy Trial
Participants undergoing radiation after breast conserving surgery for an early breast cancer (either Ductal Carcinoma In Situ (DCIS), or Early Stage Invasive breast cancer), and are at increased risk of developing a skin reaction…
- Trial name
- NCT01815476
- Testing
- Radiation Therapy Positioning Intervention
- Where
- 2 sites in Canada
- Volunteers
- 378 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Invasive Breast Cancer
Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- CTREP (NCT03247478)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University
Invasive Breast Cancer
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
This is a prospective, single-center, non-randomized, non-controlled study. The estrogen receptor (ER), progesterone receptor (PgR), HER2 status and Ki67 index of CNB specimen are critical biomarkers for making neoadjuvant…
- Trial name
- NCT02773784
- Testing
- immunohistochemistry and/or FISH
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University
Breast Cancer Invasive
No Axillary Surgery for Early Breast Cancer.
After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically.
- Trial name
- NCT03669705
- Testing
- Omitting axillary surgery in early breast cancer
- Volunteers
- 1,584 people
- Sponsor
- Lund University
Invasive Breast Cancer, Incident Breast Cancer
Overall Diet Quality and Breast Cancer Risk
The purpose of this study was to examine the relationship between indices of overall diet quality and incident breast cancer risk in a large prospective cohort of women.
- Trial name
- NCT03304171
- Volunteers
- 96,959 people
- Sponsor
- University of California, Irvine
in Situ Breast Cancer, Invasive Breast Cancer
Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study
The objective of this prospective randomized study is to perform qualitative and quantitative comparisons between the insertion of traditional suction drains (Arm: Suction drain) versus the application of absorbable adaptive…
- Trial name
- NCT01509781
- Testing
- Insertion of suction drain(s) following mastectomy, Adaptive skin sutures.
- Where
- Hungary
- Volunteers
- 400 people
- Sponsor
- National Institute of Oncology, Hungary
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma
Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer
This pilot clinical trial studies magnetic resonance thermal image guided laser interstitial thermal therapy in treating patients with breast cancer.
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT01791998
- Testing
- magnetic resonance thermal imaging, laser interstitial thermal therapy
- Where
- United States
- Sponsor
- University of Chicago
Invasive Early Breast Cancer
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years.
- Trial name
- NCT01121549
- Testing
- Aromasin
- Where
- 40 sites in Romania
- Volunteers
- 378 people
- Sponsor
- Pfizer